INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 279 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $356,452 | -20.4% | 11,273 | +2.7% | 0.00% | 0.0% |
| Q2 2023 | $447,724 | +21.3% | 10,979 | +10.9% | 0.00% | 0.0% |
| Q1 2023 | $369,010 | -0.8% | 9,901 | -7.1% | 0.00% | 0.0% |
| Q4 2022 | $372,032 | -44.3% | 10,663 | -10.7% | 0.00% | -33.3% |
| Q3 2022 | $668,000 | +21.2% | 11,943 | +12.2% | 0.00% | 0.0% |
| Q2 2022 | $551,000 | -23.3% | 10,642 | +7.8% | 0.00% | 0.0% |
| Q1 2022 | $718,000 | -44.4% | 9,875 | -9.6% | 0.00% | -40.0% |
| Q4 2021 | $1,292,000 | -12.6% | 10,925 | -0.9% | 0.01% | -28.6% |
| Q3 2021 | $1,479,000 | -7.9% | 11,026 | +11.1% | 0.01% | 0.0% |
| Q2 2021 | $1,606,000 | +90.3% | 9,920 | -5.7% | 0.01% | +75.0% |
| Q1 2021 | $844,000 | -41.6% | 10,520 | -60.4% | 0.00% | -33.3% |
| Q4 2020 | $1,444,000 | +167.4% | 26,545 | -2.2% | 0.01% | +200.0% |
| Q3 2020 | $540,000 | -4.6% | 27,145 | +0.8% | 0.00% | -33.3% |
| Q2 2020 | $566,000 | +69.5% | 26,920 | -1.3% | 0.00% | +50.0% |
| Q1 2020 | $334,000 | – | 27,270 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |